首页> 外文期刊>Modern Pathology >Therapy-related Changes of CD20|[plus]| and CD45RO|[plus]| Lymphocyte Subsets in Chronic Myeloid Leukemia (CML): An Immunohistochemical and Morphometric Study on Sequential Trephine Biopsies of the Bone Marrow
【24h】

Therapy-related Changes of CD20|[plus]| and CD45RO|[plus]| Lymphocyte Subsets in Chronic Myeloid Leukemia (CML): An Immunohistochemical and Morphometric Study on Sequential Trephine Biopsies of the Bone Marrow

机译:CD20 | [plus] |的治疗相关变化和CD45RO | [plus] |慢性髓细胞性白血病(CML)中的淋巴细胞亚群:骨髓序贯性吗啡活检的免疫组织化学和形态计量学研究

获取原文
           

摘要

Little information exists about the amount of CD45RO+-T- and CD20+-B-lymphocytes in the bone marrow of patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph1+-CML) at presentation or regarding corresponding changes during therapy. On the other hand, quantification of this cell compartment seems to be imperative for two reasons: first, the presumed association of immunocompetent lymphocyte subsets in the expansion of the leukemic cell clone; and second, a speculated relationship with the complex generation of myelofibrosis. Therefore, an immunohistological and morphometric study was performed on 219 representative trephine biopsies of the bone marrow derived from 70 patients with repeated examinations during the course of Ph1+-CML. For the identification of the different lymphocyte populations, the monoclonal antibodies UCHL-1 (CD45R0) and L26 (CD20) were applied on formaldehyde-fixed and decalcified specimens. In comparison to a control group and calculated per hematopoietic cells, the CML bone marrow showed about a 50% decrease in the total amount of lymphocytes. Determination of CD45RO+ and CD20+ subsets revealed a significant enhancement during treatment. Because of the different intervals (range, 10 to 25 mo) between first and last biopsy in the various therapeutic groups, results had to be modified by considering dynamic features. This calculation included changes of the lymphocyte subpopulations related to time. Contrasting the CD45RO+ lymphocytes, a relevant increase in the CD20+ subset could be observed after interferon- treatment or corresponding combination regimens. No significant correlations were found between fiber density at onset (first biopsy) or development of fibrosis and lymphocyte proliferations in the course of CML. Our results are in keeping with the finding that a proper immune response consistent with an increased lymphocyte growth seems to be associated with a regression of the clonally-transformed cell population. Opposed to a repeatedly discussed pathomechanism, we failed to demonstrate any quantitative relationships between the extent of lymphocyte proliferations and occurrence or progression of myelofibrosis.
机译:关于呈递费城染色体阳性慢性骨髓性白血病(Ph1 + -CML)患者的骨髓中CD45RO + -T-和CD20 + -B淋巴细胞的数量的信息很少,也没有关于治疗期间相应变化的信息。另一方面,由于以下两个原因,必须对该细胞区室进行定量分析:首先,在白血病细胞克隆的扩增中推测具有免疫能力的淋巴细胞亚群的关联;第二,推测与复杂的骨髓纤维化的发生有关。因此,对来自70例患者的219例代表性的骨髓曲布因活组织检查进行了免疫组织学和形态计量学研究,并在Ph1 + -CML过程中进行了反复检查。为了鉴定不同的淋巴细胞群,将单克隆抗体UCHL-1(CD45R0)和L26(CD20)应用在甲醛固定和脱钙的标本上。与对照组相比,按造血细胞计算,CML骨髓的淋巴细胞总量减少了约50%。 CD45RO +和CD20 +亚群的测定显示治疗期间有显着增强。由于各个治疗组的第一次和最后一次活检之间的间隔时间不同(范围为10到25 mo),必须考虑动态特征来修改结果。该计算包括与时间有关的淋巴细胞亚群的变化。与CD45RO +淋巴细胞相反,在干扰素治疗或相应的联合治疗后,可以观察到CD20 +亚群的相关增加。在CML过程中,发病时的纤维密度(首次活检)或纤维化发展与淋巴细胞增殖之间未发现显着相关性。我们的结果与这样的发现一致,即与增加的淋巴细胞生长一致的适当的免疫应答似乎与克隆转化的细胞群体的退化有关。与反复讨论的病理机制相反,我们未能证明淋巴细胞增殖程度与骨髓纤维化的发生或发展之间存在定量关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号